Conditions: Neuralgia
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 9
Healthy volunteers: no

Brief summary:
This study will explore the safety and efficacy of AGN201781 in patients with postherpetic neuralgia or post-traumatic peripheral neuralgia

Detailed description:

Arms:
arm 1: AGN201781 50 mg capsules three-time daily for 2 weeks arm 2: placebo 50 mg capsules three-times daily for 2 weeks

Interventions: intervention 1: AGN201781 intervention 2: placebo
Intervention descriptions: intervention 1: AGN201781 50 mg capsules three-times daily for 2 weeks intervention 2: placebo 50 mg capsules three-times daily for 2 weeks

Protocol document: